We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Finalizes Biosimilars Guidance, Continues to Stress ‘Stepwise’ Approach
FDA Finalizes Biosimilars Guidance, Continues to Stress ‘Stepwise’ Approach
Three years after introducing a trio of guidances explaining how sponsors must demonstrate biosimilarity to existing biological drugs, the FDA continues to stress the need for a “stepwise” approach when seeking approval.